Legend Biotech/$LEGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Ticker
$LEGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
2,700
ISIN
US52490G1022
Website
Legend Biotech Metrics
BasicAdvanced
$7.3B
-
-$1.19
0.20
-
Price and volume
Market cap
$7.3B
Beta
0.2
52-week high
$60.87
52-week low
$27.34
Average daily volume
1.9M
Financial strength
Current ratio
5.2
Quick ratio
4.291
Long term debt to equity
35.123
Total debt to equity
35.648
Interest coverage (TTM)
-11.22%
Profitability
EBITDA (TTM)
-228.34
Gross margin (TTM)
8.60%
Net profit margin (TTM)
-29.95%
Operating margin (TTM)
-32.67%
Effective tax rate (TTM)
-10.47%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-8.77%
Return on equity (TTM)
-20.00%
Valuation
Price to revenue (TTM)
9.926
Price to book
7.13
Price to tangible book (TTM)
7.15
Price to free cash flow (TTM)
-26.464
Free cash flow yield (TTM)
-3.78%
Free cash flow per share (TTM)
-149.04%
Growth
Revenue change (TTM)
112.46%
Earnings per share change (TTM)
-53.95%
3-year revenue growth (CAGR)
83.13%
3-year earnings per share growth (CAGR)
-20.52%
What the Analysts think about Legend Biotech
Analyst ratings (Buy, Hold, Sell) for Legend Biotech stock.
Bulls say / Bears say
Legend Biotech's CAR-T therapy, Carvykti, achieved a remarkable 88% year-over-year sales increase to $286 million in Q3 2024, indicating strong market adoption and revenue growth potential. (stocktitan.net)
The company secured a $100 million upfront payment from Novartis through a licensing agreement for CAR-T therapies targeting DLL3, providing substantial financial resources for further development. (businesswire.com)
Analysts maintain a 'Strong Buy' consensus with a 12-month price target of $75.17, suggesting significant upside potential from the current stock price. (stockanalysis.com)
Legend Biotech's stock hit a 52-week low of $30.16 in April 2025, reflecting market challenges and investor concerns. (investing.com)
The company reported a net loss of $125.3 million in Q3 2024, highlighting ongoing profitability challenges despite revenue growth. (stocktitan.net)
Morgan Stanley reduced its price target for Legend Biotech from $82.00 to $80.00 in March 2025, indicating tempered expectations for stock performance. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Legend Biotech Financial Performance
Revenues and expenses
Legend Biotech Earnings Performance
Company profitability
Legend Biotech News
AllArticlesVideos
Legend Biotech Corporation INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Legend Biotech Corporation (LEGN)
Accesswire·1 month ago
LEGN STOCK ALERT: Levi & Korsinsky Notifies Legend Biotech Corporation Investors of an Ongoing Investigation
Accesswire·1 month ago
Shareholders That Lost Money on Legend Biotech Corporation (LEGN) Should Contact Levi & Korsinsky about Securities Fraud Investigation - LEGN
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Legend Biotech stock?
Legend Biotech (LEGN) has a market cap of $7.3B as of July 15, 2025.
What is the P/E ratio for Legend Biotech stock?
The price to earnings (P/E) ratio for Legend Biotech (LEGN) stock is 0 as of July 15, 2025.
Does Legend Biotech stock pay dividends?
No, Legend Biotech (LEGN) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Legend Biotech dividend payment date?
Legend Biotech (LEGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Legend Biotech?
Legend Biotech (LEGN) has a beta rating of 0.2. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.